A systematic review and meta-analysis on the effects of metformin on survival outcomes and risk in women with cervical cancer

Objective: A systematic review and meta-analysis was conducted to quantitatively assess the effects of metformin on both the treatment and risk of cervical cancer in women. Materials and Methods: A search was conducted in a number of databases including CNKI, VIP, Wanfang Digital Journal Full-text Database, PubMed, Cochrane, and Web of Science. In accordance with inclusion and exclusion criteria screening in the literature, Newcastle-Ottawa scale and RevMan 5.3 software were employed to perform the meta-analysis. Results: A total of five studies taken from four articles involving 149,742 participants were finally included in meta-analysis, two random clinical trials (RCTs) and three retrospective cohort studies. Evaluation of metformin usage in two of the studies did not show significant association with five-year overall survival (OS) of patients receiving adjuvant whole-pelvic radiation therapy (WPRT) as a primary therapy compared to those. not using metformin (RR = 1.08, 95% CI 1.00-1.18, p = 0.06). In the three other studies metformin use was associated with a significant reduction in cervical cancer risk in diabetes mellitus patients (RR = 0.60, 95% CI 0.44-0.82, p = 0.001). Conclusion: Merformin use is associated with a reduction in cervical cancer risk in patients with diabetes mellitus, but is not associated with five-year OS of patients receiving WPRT. Further studies are required to confirm survival outcomes for use of metformin in cervical cancer.

Cervical cancer; Meta-analysis; Metformin; Outcomes; Systematic review

[1] Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gap- stur S.M., Habel L.A., et al.: “Diabetes and cancer: a consensus report”. CA Cancer J. Clin., 2010, 60, 207.

[2] Liu Y., Zhou H.P.: “Clinical analysis on 66 patients with type 2 diabetes mellitus combined with gynecologic malignant tumors”. Maternal and Child Health Care of China, 2013, 28, 5795.

[3] Vigneri P., Frasca F., Sciacca L., Pandini G., Vigneri R.: “Diabetes and cancer”. Endocr. Relat. Cancer, 2009, 16, 1103.

[4] Lu H., Chen H.X., Guo J.X., Yang L.L., Yuan M.L.: “Analysis of hospital infection related factors in gynecological tumor patients af- ter operation”. Clin. J. Nosocomiol., 2017, 17, 896.

[5] Zheng Y., Sun H.: “Effect of metformin combined with chemotherapy on gynecological tumors”. Prog. Obstet. Gynecol., 2016, 25, 856.

[6] Lin C.C., Yeh H.H., Huang W.L., Yan J.J., Lai W.W., Su W.P., et al.: “Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway”. Am. J. Respir. Cell. Mol. Biol., 2013, 49, 241.

[7] Wei D.H., Wang Y., Shi H.R.: “Association of p53 and mitochondrial gene with chemosensitization by metformin in ovarian cancer”. Oncotarget, 2017, 9, 2971.

[8] Perez-Lopez F.R., Pasupuleti V., Gianuzzi X., Palma-Ardiles G., Hernandez-Fernandez W., Hernandez A.V.: “Systematic review and meta-analysis of the effect of metformin treatment on overall mor- tality rates in women with endometrial cancer and type 2 diabetes mellitus”. Maturitas, 2017, 101, 6.

[9] Garcia C., Yao A., Camacho F., Balkrishnan R., Cantrell L.A.: “A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer”. Gynecol. Oncol., 2017, 146, 346.

[10] Wells G.A., Shea B., O’ Connell D., Peterson J., Welch V., Losos M., Tugwell P.: “The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses”. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

[11] Home P.D., Kahn S.E., Jones N.P., Noronha D., Beck-Nielsen H., Viberti G.: “ADOPT Study Group, RECORD Steering Committee. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials”. Diabetologia, 2010, 53, 1838.

[12] Han K., Pintilie M., Lipscombe L.L., Lega I.C., Milosevic M.F., Fyles A.W.: “Association between Metformin Use and Mortality after Cervical Cancer in Older Women with Diabetes”. Cancer Epidemiol. Biomarkers Prev., 2016, 25, 507.

[13] Li D.M., Wang L., Yuan L., Sun X.C.: “Effect of metformin on efficacy of chemoradiotherapy in patients with advanced cervical camcer combined with T2DM”. Jiangsu Med. J., 2014, 42, 1018.

[14] Tseng C.H.: “Metformin use and cervical cancer risk in female patients with type 2 diabetes”. Oncotarget, 2016, 7, 59548.

[15] Takiuchi T., Machida H., Hom M.S., Mostofizadeh S., Frimer M., Brunette L.L., Matsuo K.: “Association of Metformin Use and Survival Outcome in Women With Cervical Cancer”. Int. J. Gynecol. Cancer, 2017, 27, 1455.

[16] Hanprasertpong J., Jiamset I., Geater A., Peerawong T., Hemman W., Kornsilp S.: “The Effect of Metformin on Oncological Outcomes in Patients With Cervical Cancer With Type 2 Diabetes Mel- litus”. Int. J. Gynecol. Cancer, 2016, 27, 131.

[17] Febbraro T., Lengyel E., Romero I.L.: “Old drug, new trick: Repurposing metformin for gynecologiccancers?” Gynecol. Oncol., 2014, 135, 614.

[18] Cai H., Zhang Y., Han T.K., Everett R.S., Thakker D.R.: “Cation-selective transporters are critical to the ampk-mediated antiproliferative effects of metformin in human breast cancer cells”. Int. J. Cancer, 2016, 138, 2281.

[19] Milewicz T., Kiałka M., Mrozińska S., Ociepka A., Krzysiek J.: “Metformin—new treatment strategies for gynecologic neoplasms”. Przegl. Lek., 2013, 70, 81.

[20] Anastasi E., Filardi T., Tartaglione S., Lenzi A., Angeloni A., Morano S.: “Linking type 2 diabetes and gynecological cancer: an introductory overview”. Clin. Chem. Lab. Med., 2018, 56, 1413.

[21] Kim J., Lee J., Jang S.Y., Kim C., Choi Y., Kim A.: “Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines”. Oncol. Rep., 2016, 35, 2553.

[22] Franciosi M., Lucisano G., Lapice E., Strippoli G.F., Pellegrini F., Nicolucci A.: “Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review”. Plos One, 2013, 8, e71583.

[23] Liu F., Yan L., Zhan W., Lu Y., Chu Y., Li X., et al.: “Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis”. Oncotarget, 2017, 8, 16017.